AMEX · VNRX

VolitionRx Limited

$0.88 -$0.12 (-12.00%) 1D After hours

Key Metrics

$12.04M
Market cap
P/E · TTM
$738.69K
Revenue · TTM
−$1.24M
Net income
EPS · TTM $-0.26
Dividend yield
Free cash flow
Beta · 1Y 1.06
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Jan 30 high, the share price fell 85%.

    Peak close $5.70 on Jan 30; trough close $0.88 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -85%
  • Jul 21
    A material event was filed (Form 8-K).

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 8
    The stock moved -22.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 8
  • Feb 25
    The stock moved +25.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 25

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$12.04M
Enterprise value
Shares outstanding12.0M
52-wk range$0.22 – $7.73
Avg volume · 20D272.9K
Net cash
Book value / share$-6.62
IndustryIn Vitro & In Vivo Diagnostic Substances
ExchangeAMEX
About VolitionRx Limited
IPO dateApr 25, 2007
Employees75

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETo…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S16.30
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating 23.4%
Net -168.0%
FCF
ROE / ROIC 4.4% · —

Financial Health

Current ratio0.33
Quick ratio
Debt / equity-0.23
Debt / EBITDA
Net cash
Working capital−$9.05M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-41.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings